Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology

Samuel O. Bekoe; Samuel Asare-Nkansah; Kwabena F.M. Opuni

doi:10.1007/978-3-031-12398-6_10

Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology

Samuel O. Bekoe, Samuel Asare-Nkansah, Kwabena F.M. Opuni

Department of Pharmaceutical Chemistry

Kwame Nkrumah University of Science and Technology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The integrity of samples employed for therapeutic drug monitoring (TDM) and clinical toxicology (CT) has a significant impact on the quality of data obtained for clinical decision-making. Samples usually employed for TDM and/or CT are obtained either using invasive or non-invasive approaches, and these include blood, plasma, or serum (invasive approaches), urine, and saliva (non-invasive approaches). Lack of standard operating procedures for samples in the pre-analytical stage could lead to variabilities in analysis results because of factors such as haemolysis (blood samples), inappropriate cooling and storage (urine samples), and desiccation of saliva. Therefore, assuring the quality and integrity of samples obtained for TDM and CT studies is a requirement for reliable data suitable for informed clinical decisions for patients as well as medical emergencies. It is an irrefutable emphasis that the assurance of the quality of samples meant for TDM and CT assessments correlates strongly with the quality of data obtained for clinical interpretation and implementation of optimized care. This chapter thus addresses major concerns, regarding the quality assurance of samples for TDM and CT.

Original language	English
Title of host publication	Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology
Publisher	Springer International Publishing
Pages	161-164
Number of pages	4
ISBN (Electronic)	9783031123986
ISBN (Print)	9783031123979
DOIs	https://doi.org/10.1007/978-3-031-12398-6_10
Publication status	Published - 1 Jan 2022

Keywords

Bioanalysis
Biological samples
Clinical toxicology
Quality assurance
Therapeutic drug monitoring

Access to Document

10.1007/978-3-031-12398-6_10

Cite this

@inbook{e2e0eb6b54f748d3bdb6069f2115a5bf,

title = "Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology",

abstract = "The integrity of samples employed for therapeutic drug monitoring (TDM) and clinical toxicology (CT) has a significant impact on the quality of data obtained for clinical decision-making. Samples usually employed for TDM and/or CT are obtained either using invasive or non-invasive approaches, and these include blood, plasma, or serum (invasive approaches), urine, and saliva (non-invasive approaches). Lack of standard operating procedures for samples in the pre-analytical stage could lead to variabilities in analysis results because of factors such as haemolysis (blood samples), inappropriate cooling and storage (urine samples), and desiccation of saliva. Therefore, assuring the quality and integrity of samples obtained for TDM and CT studies is a requirement for reliable data suitable for informed clinical decisions for patients as well as medical emergencies. It is an irrefutable emphasis that the assurance of the quality of samples meant for TDM and CT assessments correlates strongly with the quality of data obtained for clinical interpretation and implementation of optimized care. This chapter thus addresses major concerns, regarding the quality assurance of samples for TDM and CT.",

keywords = "Bioanalysis, Biological samples, Clinical toxicology, Quality assurance, Therapeutic drug monitoring",

author = "Bekoe, {Samuel O.} and Samuel Asare-Nkansah and Opuni, {Kwabena F.M.}",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-12398-6_10",

language = "English",

isbn = "9783031123979",

pages = "161--164",

booktitle = "Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology

AU - Bekoe, Samuel O.

AU - Asare-Nkansah, Samuel

AU - Opuni, Kwabena F.M.

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The integrity of samples employed for therapeutic drug monitoring (TDM) and clinical toxicology (CT) has a significant impact on the quality of data obtained for clinical decision-making. Samples usually employed for TDM and/or CT are obtained either using invasive or non-invasive approaches, and these include blood, plasma, or serum (invasive approaches), urine, and saliva (non-invasive approaches). Lack of standard operating procedures for samples in the pre-analytical stage could lead to variabilities in analysis results because of factors such as haemolysis (blood samples), inappropriate cooling and storage (urine samples), and desiccation of saliva. Therefore, assuring the quality and integrity of samples obtained for TDM and CT studies is a requirement for reliable data suitable for informed clinical decisions for patients as well as medical emergencies. It is an irrefutable emphasis that the assurance of the quality of samples meant for TDM and CT assessments correlates strongly with the quality of data obtained for clinical interpretation and implementation of optimized care. This chapter thus addresses major concerns, regarding the quality assurance of samples for TDM and CT.

AB - The integrity of samples employed for therapeutic drug monitoring (TDM) and clinical toxicology (CT) has a significant impact on the quality of data obtained for clinical decision-making. Samples usually employed for TDM and/or CT are obtained either using invasive or non-invasive approaches, and these include blood, plasma, or serum (invasive approaches), urine, and saliva (non-invasive approaches). Lack of standard operating procedures for samples in the pre-analytical stage could lead to variabilities in analysis results because of factors such as haemolysis (blood samples), inappropriate cooling and storage (urine samples), and desiccation of saliva. Therefore, assuring the quality and integrity of samples obtained for TDM and CT studies is a requirement for reliable data suitable for informed clinical decisions for patients as well as medical emergencies. It is an irrefutable emphasis that the assurance of the quality of samples meant for TDM and CT assessments correlates strongly with the quality of data obtained for clinical interpretation and implementation of optimized care. This chapter thus addresses major concerns, regarding the quality assurance of samples for TDM and CT.

KW - Bioanalysis

KW - Biological samples

KW - Clinical toxicology

KW - Quality assurance

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=85158961135&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-12398-6_10

DO - 10.1007/978-3-031-12398-6_10

M3 - Chapter

AN - SCOPUS:85158961135

SN - 9783031123979

SP - 161

EP - 164

BT - Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology

PB - Springer International Publishing

ER -

Quality Assurance of Samples for Therapeutic Drug Monitoring and Clinical Toxicology

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this